Maha Radhakrishnan, M.D.

Maha Radhakrishnan, M.D.

DirectoratCandel Therapeutics· In the 2025 proxy

Maha Radhakrishnan, M.D. sits on 5 public boards.

Boards1

  • Candel TherapeuticsDirector · 0 yr on the boardIndependentAudit—Paid as an executive

Board seats come from each company's latest proxy statement.

Experience

  1. Candel TherapeuticsPublic company · 1 yr
    • Director2025 – Present · 1 yrStock in role -1%
  2. Entrada Therapeutics, Inc.Public company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  3. CandelPublic company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  4. Alto Neuroscience, Inc.Public company · 1 yr
    • Director2024 – 2025 · 1 yrNo stock prices for these years
  5. Minovia TherapeuticsPublic company · 2 yr
    • Director2023 – 2025 · 2 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?